Literature DB >> 1351491

Immunocytochemical analysis of chromaffin cell proliferation in vitro.

A S Tischler1, L A Ruzicka, J C Riseberg.   

Abstract

The bromodeoxyuridine (BrdU) incorporation technique for immunocytochemical labeling of S-phase nuclei was optimized for the study of chromaffin cell proliferation. Sequential fixation in ethanol followed by paraformaldehyde, and the use of DNAse to render incorporated BrdU accessible to antibody, permitted permanent double staining for BrdU and tyrosine hydroxylase. The efficacy of the technique was demonstrated in microcultures of dissociated neonatal rat adrenal glands, in which chromaffin cells exhibited proliferative responses to nerve growth factor and fibroblast growth factor similar to those previously demonstrated by autoradiography. Growth factor responsiveness was observed in both serum-containing and serum-free medium.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351491     DOI: 10.1177/40.7.1351491

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  12 in total

1.  What happens in "chromospheres"?

Authors:  Arthur S Tischler
Journal:  Stem Cells Transl Med       Date:  2013-12       Impact factor: 6.940

2.  Different responses to mitogenic agents by Adult rat and human chromaffin cells in vitro.

Authors:  Arthur S Tischler; Jocelyn C Riseberg
Journal:  Endocr Pathol       Date:  1993-03       Impact factor: 3.943

3.  Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice.

Authors:  James F Powers; Karel Pacak; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1996-08

5.  The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain.

Authors:  C Higgins; S Chatterjee; V Cherington
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  The ret-Activating Ligand GDNF Is Differentiative and Not Mitogenic for Normal and Neoplastic Human Chromaffin Cells In Vitro.

Authors:  James F. Powers; Panayiotis Tsokas; Arthur S. Tischler
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

7.  Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.

Authors:  Alessio Giubellino; Petra Bullova; Svenja Nölting; Hana Turkova; James F Powers; Qingsong Liu; Sylvie Guichard; Arthur S Tischler; Ashley B Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2013-01-10       Impact factor: 4.736

8.  Isolation, characterization, and differentiation of progenitor cells from human adult adrenal medulla.

Authors:  Magda M Santana; Kuei-Fang Chung; Vladimir Vukicevic; Joana Rosmaninho-Salgado; Waldemar Kanczkowski; Vera Cortez; Klaus Hackmann; Carlos A Bastos; Alfredo Mota; Evelin Schrock; Stefan R Bornstein; Cláudia Cavadas; Monika Ehrhart-Bornstein
Journal:  Stem Cells Transl Med       Date:  2012-10-29       Impact factor: 6.940

9.  Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse.

Authors:  Catherine F Li; Jeffrey R MacDonald; Robert Y Wei; Jocelyn Ray; Kimberly Lau; Christopher Kandel; Rachel Koffman; Sherilyn Bell; Stephen W Scherer; Benjamin A Alman
Journal:  BMC Genomics       Date:  2007-04-03       Impact factor: 3.969

10.  Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.

Authors:  James F Powers; Parimal G Korgaonkar; Stephanie Fliedner; Alessio Giubellino; Karel Pacak; G Gary Sahagian; Arthur S Tischler
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.